Endothelin receptors (ETA and ETB) are G-protein coupled receptors activated 17 by endothelin-1 and are involved in blood pressure regulation. IRL2500 is a peptide-18 mimetic of the C-terminal tripeptide of endothelin-1, and has been characterized as a 19 potent ETB-selective antagonist, which has preventive effects against brain edema. Here, 20
effects against brain edema in the acute phase of brain insults [13] [14] [15] [16] . 48
To date, most endothelin receptor antagonists have been developed based on 49 bosentan 17, 18 . The ETR antagonists that have been developed till now are mostly N-50 -4 -heterocyclic sulfonamides with similar structures and molecular weights, and non-51 sulfonamide antagonists (atrasentan, ambrisentan, darusentan, and enrasentan) still retain 52 high similarities with each other and with the sulfonamides 7 . Therefore, the ETR agents 53 are chemically very similar, and expanded chemical space should be exploited. IRL2500 54 is a peptide ETR antagonist developed based on the partial structure of ET-1 19 , rather than 55 bosentan. IRL2500 has been characterized as an ETB-selective antagonist with an IC50 56 value of 1.2 nM 20 , which shows higher affinity than that of bosentan. In an animal model, 57 the intracerebroventricular administration of IRL2500 attenuated cold injury-mediated 58 brain edema and disruption of the blood-brain barrier, indicating the neuroprotective 59 effect of IRL2500 14, 15 . An understanding of the IRL2500 binding mode would facilitate 60 the expansion of the chemical space of ET agents. 61
We previously reported the crystal structures of the ETB receptor bound to ET-1 21 62 and bosentan 22 ; however, both the binding mode and ETB-selectivity of IRL2500 63 remained to be elucidated. Here, we present the crystal structure of the ETB receptor in 64 complex with IRL2500. This structure revealed the unique binding mode of IRL2500, 65 which differs from those of ET-1 and bosentan. Structure-guided functional analyses 66 clearly demonstrate that IRL2500 functions as an inverse agonist for the ETB receptor, 67 and thus will provide the basis for design of inverse agonists for other class A GPCRs. 68 69 70 -5 -
Results 71
Overall structure 72
For crystallization, we used the previously established, thermostabilized ETB 73 receptor (ETB-Y4) 22, 23 . The IC50 value of IRL2500 for ETB-Y4 was similar to that for the 74 wild type receptor in the TGFα shedding assay 24 (Fig. 1 ), suggesting that the 75 themostabilizing mutations minimally affect the IRL2500 binding. In contrast, the IC50 76 value of IRL2500 for the ETA receptor is over 3 M (Fig. 1) , indicating that IRL2500 has 77 over 100-fold ETB-selectivity, consistent with the previous pharmacological analysis 20 . 78
To facilitate crystallization, we replaced the third intracellular loop (ICL3) of the receptor 79 with minimal T4 Lysozyme 25 (ETB-Y4-mT4L). Using in meso crystallization 26 , we 80 obtained crystals of ETB-Y4-mT4L in complex with IRL2500 ( Supplementary Fig. 1a, b) . 81
In total, 58 datasets were collected and merged by the data processing system KAMO 27 . 82
Eventually, we determined the ETB structure in complex with IRL2500 at 2.7 Å resolution, 83 by molecular replacement using the antagonist-bound ETB structure (PDB code: 5X93) 84 (Table 1) . 85
The overall structure consists of the canonical 7 transmembrane helices (TM), the 86 amphipathic helix 8 at the C-terminus (H8), and two antiparallel β-strands in the 87 extracellular loop 2 (ECL2), as in the previously determined ETB structures (Fig. 2a ). The 88 IRL2500-bound structure is similar to the bosentan-bound structure, rather than the ET-89 1-bound structure (R.M.S.D. values for Cα atoms=1.34 and 1.95 Ǻ, respectively), 90 reflecting the inactive conformation. We observed a remarkable difference in the 91 conformation of ECL2. The β strands are opened up by 9 Å, as compared with those in 92 -6 -the ligand-free structure ( Fig. 2b and Supplementary Fig. 2a ), and are the widest among 93 the peptide-activated class A GPCRs ( Supplementary Fig. 2b ). This structural feature 94 indicates the innate flexibility of ECL2, to capture the large peptide ligand endothelin, in 95 the inactive conformation of the ETB receptor. 96
97

IRL2500 binding site 98
We first describe the IRL2500 binding mode. IRL2500 consists of a tryptophan, 99 a 3,5-dimethylbenzoyl group, and a biphenyl group 19 , which are connected by two peptide 100 bonds ( Fig. 2c ). IRL2500 binds to the transmembrane binding cleft exposed to the 101 extracellular side, with a clear electron density in the Fo − Fc omit map (Supplementary 102 Fig. 3a, b ). The carboxylate group of the tryptophan moiety in IRL2500 forms salt bridges 103 with K182 3.33 and R343 6.55 (superscripts indicate Ballesteros-Weinstein numbers 28 ) ( Fig.  104 2c, d). The tryptophan side chain of IRL2500 hydrogen bonds with the carbonyl group of 105 the N158 2.61 side chain, and forms extensive van der Waals interactions with N158 2.61 , 106 K161 2.64 , V177 3.28 , P178 3.29 , and F240 4.64 (Fig. 2d ). The dimethyl phenyl group of 107 IRL2500 forms van der Waals interactions with the hydrophobic pocket, and is 108 surrounded by V185 3.36 , L277 5.42 , Y281 5.46 , W336 6.48 , L339 6.51 , and H340 6.52 . The 109 biphenyl group penetrates deeply into the receptor core proximal to D147 2.50 , and forms 110 van der Waals interactions with D147 2.50 , H150 2.53 , W336 6.48 , and S376 7.43 . Overall, the 111 carboxylate of IRL2500 is specifically recognized by the positively charged residues of 112 the ETB receptor, and the other moieties fill the space within the transmembrane binding 113
pocket. 114
To elucidate the structural basis for the ETB-selectivity of IRL2500, we compared 115 -7 -the residues constituting the IRL2500 binding site between the ETB and ETA receptors 116 ( Fig. 3a and Supplementary Fig. 4 ). Although most of the residues are conserved, three 117 residues are replaced with bulkier residues in the ETA receptor (H150Y, V177F, and 118 S376T). These replacements may cause steric clashes with the aromatic groups of 119 IRL2500 and reduce its affinity. To investigate this hypothesis, we measured the IC50 120 values of IRL2500 for the H150Y, V177F, and S346T ETB receptor mutants. These 121 mutants showed similar responses for ET-1 in the TGFα shedding assay (Supplementary 122 Fig. 5 ), and only V177F showed a 4-fold higher IC50 value with IRL2500 ( Fig. 3b ). These 123 data suggest that the V177F mutation in the ETA receptor sterically clashes with the 124 tryptophan moiety of IRL2500 and reduces its affinity, thus partially accounting for the 125 ETB-selectivity of IRL2500. This is consistent with the previous study, in which the 126 replacement of the tryptophan moiety with the smaller valine residue in IRL2500 127 weakened its ETB-selectivity 29 . 128 129
Comparison of the binding modes of IRL2500, ET-1, and bosentan 130
IRL2500 is designed to mimic the Y13, F14, I19, I20, and W21 residues in ET-131 1, which play critical roles in ligand binding to the ETB receptor 19 . The tryptophan and 132 dimethyl phenyl group of IRL2500 seem to be equivalent to W21 and I20 in ET-1, 133 respectively, while the biphenyl group of IRL2500 seems to be equivalent to F14 and I19 134 of ET-1. However, a comparison between IRL2500 and ET-1 binding revealed an 135 unexpected difference in their binding interactions (Fig. 4a ). The carboxylate of the 136 tryptophan in IRL2500 superimposes well with that of W21 in ET-1, and is coordinated 137 by similar positively charged residues. The tryptophan moiety and dimethyl phenyl group 138 -8 -of IRL2500 superimpose well with I20 and W21 of ET-1, respectively. In contrast, the 139 biphenyl group of IRL2500 penetrates into the receptor core, in an opposite manner to 140 the F14 and I19 of ET-1. Overall, the electrostatic interactions between the carboxylates 141 and the positively charged residues are conserved in IRL2500 and ET-1 binding, but the 142 other moieties form totally distinct interactions with the receptor. The volume of the 143 ligand binding pocket in the ligand-free structure is large, thereby allowing the aromatic 144 moieties of IRL2500 to flip. 145 IRL2500 has distinct chemical moieties as compared with bosentan, because 146 IRL2500 was not developed based on bosentan. To reveal the similarities and differences 147 in their binding modes, we compared the binding modes of IRL2500 and bosentan in 148 detail ( Fig. 4b, c ). The carboxylate of IRL2500 and the sulfonamide of bosentan are 149 similarly coordinated by the positively charged residue R343 6.55 , suggesting that this 150 electrostatic interaction is a common feature of the antagonist binding to the ETB receptor. 151
In addition, like bosentan, the aromatic moieties of IRL2500 fit within the local 152 hydrophobic pockets in the ETB receptor. Overall, IRL2500 has moieties that form similar 153 binding interactions to those of bosentan. However, bosentan lacks the moiety 154 corresponding to the biphenyl group of IRL2500, which deeply penetrates into the 155 receptor core. Thus, IRL2500 fits into the pocket more tightly as compared with bosentan, 156 contributing to its higher affinity. 157
158
IRL2500 function an inverse agonist for ETB 159
To obtain mechanistic insights into the receptor inactivation by IRL2500, we 160 compared the ETB structures bound to ET-1, bosentan, and IRL2500. Previous structural 161 -9 -studies showed that ET-1 binding induces the inward moment of the extracellular portion 162 of TM6 including W336 6.48 , leading to receptor activation on the intracellular side 21 (Fig.  163 5a). Bosentan binding sterically prevents the inward motion of W336 6.48 with its 2-164 methoxyphenoxy group, and thus functions as an antagonist 22 (Fig. 5b ). The 165 dimethylphenyl group of IRL2500 superimposes well with the 2-methoxyphenoxy group 166 of bosentan and similarly prevents the inward motion. Moreover, the dimethyl phenyl and 167 biphenyl groups of IRL2500 sandwich the W336 6.48 side chain, tightly preventing its 168 inward rotation. These observations suggest that IRL2500 strongly prevents the transition 169 to the active state, as compared with bosentan, thereby possibly working as an inverse 170 agonist that reduces the basal activity. 171
To investigate the inverse agonist activity of IRL2500 for the ETB receptor, we 172 first measured ligand-induced AP-TGF release responses. The EC50 value of the agonist 173
ET-1 was 0.11 nM, while IRL2500 and the antagonist bosentan did not change the 174 receptor activation level ( Fig. 5c ). These data suggested that IRL2500 does not have the 175 inverse agonist activity or that the assay is not sensitive enough to detect inverse agonist 176 activity. Indeed, we observed that the basal activity of the ETB receptor was very low in 177 the assay ( Fig. 5d ) and thus we could not distinguish whether IRL2500 functions as an 178 antagonist or an inverse agonist by this assay. 179 Therefore, we tried the same assay using a constitutively active mutant of the ETB 180 receptor. Constitutively active mutant GPCRs have been employed in pharmacological 181 characterizations of inverse agonists 30 , because such mutant GPCRs allow the assay to 182 measure signals in a larger detection window. The substitution of the highly conserved 183 L3.43 to glutamine has been identified as a causative activating mutation in the TSHR 31 184 -10 -and CYSLTR2 32 genes, which are related to hyperthyroidism and uveal melanoma, 185 respectively. Therefore, we transferred the L3.43Q mutation into ETB (ETB-L192 3.43 Q) 186 and examined its constitutive activity. We found that ETB-L3.43Q induced spontaneous 187 AP-TGFα release in a plasmid volume-dependent manner (Fig. 5d ), indicating that 188 L3.43Q works as a constitutive active mutation in the ETB receptor. We evaluated the 189 dose response effects of bosentan and IRL2500, using the constitutive active mutant ETB-190 L3.43Q (Fig. 5e ). Again, the antagonist bosentan did not change the receptor activation 191 from the baseline level, whereas IRL2500 reduced the basal activity (EC50=1.2 nM). 192
These data indicate that IRL2500 works as a potent inverse agonist for the ETB receptor, 193 consistent with the structural observations. The biphenyl group of IRL2500 prevents the 194 inward motion of W336 6.48 and stabilizes the inactive conformation, and thus IRL2500 195 functions as an inverse agonist. We have determined the crystal structure of the ETB receptor in complex with the 207 peptide compound IRL2500, and thus elucidated the detailed receptor interactions and 208 the structural basis for its ETB selectivity. Although IRL2500 is designed to mimic the 209 partial structure of ET-1, the binding mode is quite different. Moreover, using the 210 constitutively active mutant that we established in the current study, we first revealed that 211 IRL2500 functions as a potent inverse agonist for the ETB receptor, and provided the 212 structural basis for the inverse agonistic mechanism. 213 Small-molecule ETR antagonists have been developed over the years; however, 214 most ETR antagonists have been designed based on bosentan. Thus, the presently 215 available ET agents are chemically very similar. IRL2500 was developed based on ET-1 216 and has totally distinct chemical moieties, as compared with bosentan. However, the 217 comparison of the IRL2500 and bosentan binding modes revealed the unexpected 218 similarity in their binding interactions. This observation suggests that the charge-219 complementary interactions in the center of the pocket form the core of the receptor-220 antagonist interactions, and the other aromatic moieties fit the local hydrophobic pocket. 221
The ligand binding pocket in the inactive ETB structures is larger than those in other 222 GPCR structures, and thus aromatic moieties may be necessary to fit well within the 223
pocket. 224
We revealed that the biphenyl group of IRL2500 penetrates deeply into the 225 receptor core proximal to D147 2.50 , preventing the inward motion of W336 6.48 in TM6, 226 and thus IRL2500 functions as an inverse agonist ( Fig. 6a ). This D2.50 constitutes a 227 -12 -sodium binding site adjacent to the orthosteric site, which is highly conserved among the 228 class A GPCRs 33 . Sodium has negative allosteric effects on ligand binding in most class 229 A GPCRs, by stabilizing the inactive conformations. Therefore, this sodium binding site 230 is the hot spot for the design of allosteric modulators and inverse agonists to fix receptors 231 in the inactive conformations. In the BLT1 structure bound to the inverse agonist BIIL260, 232 the benzamidine group of BIIL260 directly hydrogen bonds with D2.50, stabilizing the 233 inactive conformation instead of the sodium 34 (Fig. 6b ). The biphenyl group of IRL2500 234 superimposes well with the benzamidine group of BIIL260 ( Fig. 6c ). Although the 235 biphenyl group of IRL2500 does not form any hydrogen-bonding interactions with the 236 receptor, it prevents the conformational change around the D2.50 in a similar manner to 237 the benzamidine moiety of BIIL260. For the design of effective inverse agonists, the 238 biphenyl moiety would be also useful as a modulation part along with another moiety that 239 exerts specific and tight binding to the orthosteric site, as well as a benzamidine group. 
Materials and methods 248
Expression and purification 249
The haemagglutinin signal peptide, followed by the Flag epitope tag 250 (DYKDDDDK) and a nine-amino-acid linker, was added to the N-terminus of the 251 receptor, and a tobacco etch virus (TEV) protease recognition sequence was introduced 252 between G57 and L66, to remove the disordered N-terminus during the purification 253 process. The C-terminus was truncated after S407, and three cysteine residues were 254 mutated to alanine (C396A, C400A, and C405A) to avoid heterogeneous palmitoylation. 255
To improve crystallogenesis, we introduced four thermostabilizing mutations () and 256 inserted minimal T4 lysozyme 25 into intracellular loop 3, between L303 5.68 and L311 6.23 257
The thermostabilized construct ETB-Y4-mT4L was subcloned into a modified 259 pFastBac vector, with the resulting construct encoding a TEV cleavage site followed by 260 a GFP-His 10 tag at the C-terminus. The recombinant baculovirus was prepared using the 261 Bac-to-Bac baculovirus expression system (Invitrogen). Sf9 insect cells were infected 262 with the virus at a cell density of 4.0 × 10 6 cells per millilitre in Sf900 II medium, and Similarly, for the measurement of inverse agonist activity, the cells were mixed with 10 332 µl of the assay buffer, followed by the addition of serially diluted IRL2500, and incubated 333 for 4 h before the transfer of the conditioned media. The AP reaction solution (10 mM p-334 nitrophenylphosphate (p-NPP), 120 mM Tris-HCl (pH 9.5), 40 mM NaCl, and 10 mM 335 -17 -MgCl2) was dispensed into the cell plates and the CM plates (80 µl per well). The 336 absorbance at 405 nm (Abs405) of the plates was measured, using a microplate reader 337 (SpectraMax 340 PC384, Molecular Devices), before and after a 1 h incubation at room 338 temperature. AP-TGFα release was calculated as described previously 22 The ET-1-and IRL2500-bound receptors are shown as pink and sky blue ribbons, 515 respectively. IRL2500 is shown as a stick model. ET-1 is shown as a magenta ribbon with 516 stick models of the peptide residues (Y13, F14, I19, I20, and W21). b, c, Binding pockets 517 for bosentan (b) and IRL2500 (c). The bosentan-bound receptor (PDB code: 5XPR) is 518 shown as a thin orange ribbon model. The residues involved in bosentan binding (D154 2.57 , 519 Q181 3.32 , K182 3.33 , K273 5.38 , W336 6.48 , and R343 6.55 ) and D147 2.50 are shown as sticks. 520
Bosentan is shown as an orange stick model. IRL2500 and the IRL2500-bound receptor 521 are coloured as in panel (a). The residues involved in IRL2500 binding (N158 2.61 , 522 K182 3.33 , R343 6.55 , D147 2.50 , and W336 6.48 ) are shown as sticks. TM1   TM2  TM3   TM4   TM5   TM7   TM1   TM2   TM3   TM4  TM5   TM6   TM1   TM2   TM5   TM6   TM7   TM1   TM3  TM5   TM6   TM4   ECL2 W21   F14   Y13   TM2   TM3   TM4   TM5  TM6   TM2   TM4   TM5  TM6   TM2   TM4   TM5   TM1 
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